GlucoTrack Inc
GCTK4.490USD
-0.010-0.22%
Close 12/24, 13:00（ET）Quotes delayed by 15 min
4.04MMarket Cap
LossP/E TTM
More Details of GlucoTrack Inc Company
Glucotrack, Inc. is focused on the design, development, and commercialization of technologies for people with diabetes. The Company is engaged in developing a long-term Implantable Continuous Blood Glucose Monitor (CBGM) for people living with Type 1 diabetes and insulin-dependent Type 2 diabetes. Its CBGM is a long-term, implantable system that continually measures blood glucose levels with a sensor longevity of 3 years, no on-body wearable component and with minimal calibration. Its CBGM technology allows for a less burdensome approach to glucose monitoring. It has also completed four animal studies with evolving prototype systems, all four of which consistently demonstrated a simple implant procedure, functionality, and safety. The Company has also demonstrated continuous glucose sensing in the epidural space via two additional animal trials, both of which demonstrated a simple implant procedure, functionality, and safety.
GlucoTrack Inc Info
Ticker SymbolGCTK
Company nameGlucoTrack Inc
IPO dateApr 09, 2013
CEOGoode (Paul V)
Number of employees11
Security typeOrdinary Share
Fiscal year-endApr 09
Address301 Rt 17 North
CityRUTHERFORD
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code07070
Phone197286757878
Websitehttps://glucotrack.com/
Ticker SymbolGCTK
IPO dateApr 09, 2013
CEOGoode (Paul V)
Company Executives of GlucoTrack Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Andrew K. Balo
Mr. Andrew K. Balo
Independent Director
Independent Director
1.28K
--
Dr. Victoria E. Carr-Brendel, Ph.D.
Dr. Victoria E. Carr-Brendel, Ph.D.
Independent Director
Independent Director
--
--
Ms. Erin Carter
Ms. Erin Carter
Independent Director
Independent Director
--
--
Mr. Luis J. Malave
Mr. Luis J. Malave
Independent Director
Independent Director
--
--
Mr. Paul V. Goode, Ph.D.
Mr. Paul V. Goode, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Mr. Peter C. Wulff
Mr. Peter C. Wulff
Chief Financial Officer, Treasurer, Secretary
Chief Financial Officer, Treasurer, Secretary
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Andrew K. Balo
Mr. Andrew K. Balo
Independent Director
Independent Director
1.28K
--
Dr. Victoria E. Carr-Brendel, Ph.D.
Dr. Victoria E. Carr-Brendel, Ph.D.
Independent Director
Independent Director
--
--
Ms. Erin Carter
Ms. Erin Carter
Independent Director
Independent Director
--
--
Mr. Luis J. Malave
Mr. Luis J. Malave
Independent Director
Independent Director
--
--
Mr. Paul V. Goode, Ph.D.
Mr. Paul V. Goode, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Mr. Peter C. Wulff
Mr. Peter C. Wulff
Chief Financial Officer, Treasurer, Secretary
Chief Financial Officer, Treasurer, Secretary
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Wed, Dec 3
Updated: Wed, Dec 3
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
John A Ballantyne Rev Trust
5.02%
Alerus Financial, N.A.
0.55%
Malave (Luis)
0.31%
Geode Capital Management, L.L.C.
0.27%
Balo (Andrew K)
0.14%
Other
93.71%
Shareholders
Shareholders
Proportion
John A Ballantyne Rev Trust
5.02%
Alerus Financial, N.A.
0.55%
Malave (Luis)
0.31%
Geode Capital Management, L.L.C.
0.27%
Balo (Andrew K)
0.14%
Other
93.71%
Shareholder Types
Shareholders
Proportion
Corporation
5.07%
Individual Investor
0.61%
Bank and Trust
0.55%
Investment Advisor/Hedge Fund
0.33%
Hedge Fund
0.09%
Research Firm
0.05%
Investment Advisor
0.02%
Other
93.29%
Institutional Shareholding
Updated: Mon, Dec 8
Updated: Mon, Dec 8
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
26
7.28K
0.76%
--
2025Q3
28
7.28K
0.76%
--
2025Q2
28
7.28K
1.20%
+66.00
2025Q1
23
7.21K
0.06%
+6.96K
2024Q4
20
755.00
0.61%
+709.00
2024Q3
17
46.00
3.59%
+21.00
2024Q2
14
25.00
3.31%
-106.00
2024Q1
15
131.00
2.58%
+16.00
2023Q4
13
104.00
10.94%
-274.00
2023Q3
12
378.00
10.40%
+19.00
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
John A Ballantyne Rev Trust
45.73K
5.08%
+1.00
+0.00%
Sep 23, 2025
Malave (Luis)
2.86K
0.32%
-736.00
-20.48%
Sep 23, 2025
Balo (Andrew K)
1.36K
0.15%
-2.05K
-60.08%
Sep 23, 2025
Carter (Erin Catherine)
1.15K
0.13%
-613.00
-34.81%
Sep 23, 2025
Tower Research Capital LLC
1.77K
0.2%
+1.77K
--
Jun 30, 2025
Sabby Management, LLC
539.00
0.06%
+539.00
--
Dec 31, 2024
Alma Diversified Holdings LLC
429.00
0.05%
--
--
Sep 05, 2024
View more
Related ETFs
Name
Proportion
No Data
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Jun 12, 2025
Merger
60→1
Jan 30, 2025
Merger
20→1
Jan 30, 2025
Merger
20→1
Jan 30, 2025
Merger
20→1
Jan 30, 2025
Merger
20→1
May 15, 2024
Merger
5→1
Date
Type
Ratio
Jun 12, 2025
Merger
60→1
Jan 30, 2025
Merger
20→1
Jan 30, 2025
Merger
20→1
Jan 30, 2025
Merger
20→1
Jan 30, 2025
Merger
20→1
May 15, 2024
Merger
5→1
May 15, 2024
Merger
5→1
May 15, 2024
Merger
5→1
May 15, 2024
Merger
5→1
FAQs
Who are the top five shareholders of GlucoTrack Inc?
The top five shareholders of GlucoTrack Inc are:
John A Ballantyne Rev Trust holds 45.73K shares, accounting for 5.08% of the total shares.
Malave (Luis) holds 2.86K shares, accounting for 0.32% of the total shares.
Balo (Andrew K) holds 1.36K shares, accounting for 0.15% of the total shares.
Carter (Erin Catherine) holds 1.15K shares, accounting for 0.13% of the total shares.
Tower Research Capital LLC holds 1.77K shares, accounting for 0.20% of the total shares.
John A Ballantyne Rev Trust holds 45.73K shares, accounting for 5.08% of the total shares.
Malave (Luis) holds 2.86K shares, accounting for 0.32% of the total shares.
Balo (Andrew K) holds 1.36K shares, accounting for 0.15% of the total shares.
Carter (Erin Catherine) holds 1.15K shares, accounting for 0.13% of the total shares.
Tower Research Capital LLC holds 1.77K shares, accounting for 0.20% of the total shares.
What are the top three shareholder types of GlucoTrack Inc?
The top three shareholder types of GlucoTrack Inc are:
John A Ballantyne Rev Trust
Alerus Financial, N.A.
Malave (Luis)
John A Ballantyne Rev Trust
Alerus Financial, N.A.
Malave (Luis)
How many institutions hold shares of GlucoTrack Inc (GCTK)?
As of 2025Q4, 26 institutions hold shares of GlucoTrack Inc, with a combined market value of approximately 7.28K, accounting for 0.76% of the total shares. Compared to 2025Q3, institutional shareholding has increased by -0.00%.
What is the biggest source of revenue for GlucoTrack Inc?
In --, the -- business generated the highest revenue for GlucoTrack Inc, amounting to -- and accounting for --% of total revenue.
